Abstract
Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Current Cancer Therapy Reviews
Title:Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Volume: 11 Issue: 2
Author(s): Rony Benson, Supriya Mallick, K.P. Haresh, P.K. Julka and G.K. Rath
Affiliation:
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Abstract: Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Export Options
About this article
Cite this article as:
Benson Rony, Mallick Supriya, Haresh K.P., Julka P.K. and Rath G.K., Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203201
DOI https://dx.doi.org/10.2174/1573394711666151022203201 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Estrogen Regulation of Adipose Tissue Functions: Involvement of Estrogen Receptor Isoforms
Infectious Disorders - Drug Targets 10 Years of SELDI: What Have we Learnt?
Current Proteomics 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum
Current Neuropharmacology Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences
Current Drug Delivery Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy The Emergence of Non-coding RNAs as Versatile and Efficient Therapeutic Tools
Current Gene Therapy Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Inhibition of Human 5-Lipoxygenase and Anti-Neoplastic Effects by 2-Amino-1,4-Benzoquinones
Medicinal Chemistry Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer
Current Pharmaceutical Design Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Apoptosis Following Photodynamic Tumor Therapy: Induction, Mechanisms and Detection
Current Pharmaceutical Design Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry